If you like this presentation – show it...
3 Stocks That Were Huge Winners This Week
1. Sangamo BioSciences (NASDAQ: SGMO) Sangamo BioSciences is a clinical stage biotechnology company. The company is developing drugs that treat HIV and Alzheimer’s disease, and is working on gene editing and gene writing therapies to address rare indications. Sangamo BioSciences research & development partner’s include Biogen Idec and Shire Plc.
Here’s What You Need To Know Shares jumped after it reported Q4 & 2014 results. Revenue grew from $24.1 million in 2013 to $45.9 million in 2014. Growth was driven by collaboration revenue from Biogen Idec & Shire Plc. Guidance is for revenue of between $60 million & $70 million in 2015. The company has no approved drugs on the market. Its most advanced drugs are in midstage phase 2 trials.
2. Portola Pharmaceuticals Portola Pharmaceuticals is a clinical stage biotechnology company. The company is developing a factor Xa anticoagulant and a factor Xa anticoagulant reversal agent for use in heart disease and post-operative patients. Its reversal agent research trials are being partially funded by Johnson & Johnson, Pfizer Inc., and Bristol-Myers Squibb.
Here’s What You Need To Know Shares soared after it updated investors on the progress of its anticoagulant. Betrixaban phase 3 trial continues. Enrollment complete by year end. Data in 2016. The company previously reported phase 3 success for its factor Xa reversal agent. Reverses J&J’s Xarelto. Reverses Pfizer & Bristol-Myer’s Eliquis. The company has no approved drugs on the market yet.
3. Molina Healthcare Molina Healthcare is a health insurance company. The company generates the majority of its revenue by running state Medicaid programs. Enrollment in Medicaid has grown by 10 million people since the Affordable Care Act’s Medicaid expansion program launched in 2013.
Here’s What You Need To Know Shares surged after Molina reported its Q4 and 2014 results. 2014 sales up 47% to $9.7 billion. 2014 EPS up 35% to $1.30 (GAAP basis). Membership increased 36% in 2014. 700,000 newly covered. Member growth led by California, Illinois, & Washington. 18% increase in premium revenue per member. Guidance is for $14.3 billion in revenue and for diluted EPS of $2.35 per share in 2015. Adjusted EPS forecast is for $4.60.
Six stock picks poised for incredible growth Six stock picks poised for incredible growth Six stock picks poised for incredible growth Leaked: This coming blockbuster will make every biotech jealous.